» Articles » PMID: 24697314

In Search of an Unstimulated Thyroglobulin Baseline Value in Low-risk Papillary Thyroid Carcinoma Patients Not Receiving Radioactive Iodine Ablation

Overview
Journal Thyroid
Date 2014 Apr 5
PMID 24697314
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The clinical use of serum thyroglobulin (Tg) as a tumor marker in papillary thyroid cancer (PTC) patients following total thyroidectomy continues to evolve, due in part to the introduction of more sensitive (second generation) Tg immunometric assays (Tg(2G)IMA, functional sensitivity ≤ 0.10 ng/mL), and the implementation of new recommendations against radioactive iodine ablation (RAIA) for patients at the lowest risk of recurrence. As a result, there is a need to establish the optimal timing and interpretation of serum Tg values while on levothyroxine-induced suppression of thyrotropin (TSH) in thyroidectomized PTC patients with a thyroid remnant. This study examines the pattern of decline and eventual baseline value of unstimulated Tg (uTg) concentrations following total thyroidectomy in patients with low-risk PTC who did not receive RAIA.

Methods: The medical records of consecutive patients with thyroid cancer seen at the Los Angeles County + USC Medical Center were retrospectively reviewed. Serial uTg and TSH values from Tg-antibody negative low-risk PTC patients treated with total thyroidectomy and no RAIA were analyzed. Patients were stratified by degree of TSH suppression to assess the effect on uTg. Serial postoperative uTg values were evaluated for the temporal pattern of decline and ultimate baseline. Patients with medullary thyroid cancer (MTC) were studied as a surgical reference group.

Results: Records from 577 consecutive thyroid cancer patients were reviewed, of which 36 met all criteria for inclusion. By 6 months, uTg fell to <0.5 ng/mL in 61% of patients and all patients demonstrated uTg < 0.5 ng/mL 2 years after surgery. During a median follow up of 5.7 years, uTg values remained below this level. The median uTg values in patients with papillary microcarcinoma, PTC, and MTC were similar at 0.11, 0.12, and 0.09 ng/mL, respectively. Further decline in uTg was not observed once the TSH was <0.5 mIU/L.

Conclusions: The uTg values during TSH suppression in Tg antibody-negative, low-risk PTC patients who did not receive RAIA were below 0.5 ng/mL by 6 months postoperatively in most cases and remained stable over the duration of patient follow-up.

Citing Articles

Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.

Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M Eur J Nucl Med Mol Imaging. 2023; 50(9):2767-2774.

PMID: 37121981 PMC: 10317893. DOI: 10.1007/s00259-023-06239-8.


Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer.

Pabst K, Seifert R, Hirmas N, Broecker-Preuss M, Weber M, Fendler W Endocr Connect. 2022; 12(2).

PMID: 36507775 PMC: 9880903. DOI: 10.1530/EC-22-0312.


Strategies for Radioiodine Treatment: What's New.

Sparano C, Moog S, Hadoux J, Dupuy C, Al Ghuzlan A, Breuskin I Cancers (Basel). 2022; 14(15).

PMID: 35954463 PMC: 9367259. DOI: 10.3390/cancers14153800.


The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis.

Giovanella L, Garo M, Albano D, Gorges R, Ceriani L Endocr Connect. 2022; 11(4).

PMID: 35245206 PMC: 9066573. DOI: 10.1530/EC-21-0648.


Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assays.

Broecker-Preuss M, Mehnert I, Gilman E, Herrmann K, Weber M, Gorges R Pract Lab Med. 2021; 26:e00250.

PMID: 34386567 PMC: 8342782. DOI: 10.1016/j.plabm.2021.e00250.